UCB to sell Kremers Urban to private equity for US$1.53bn

Published: 10-Nov-2014
Finance Pharmaceutical

Belgian company will focus on its core business in neurology and immunology

UCB is selling its US speciality generics business Kremers Urban to private equity firms Advent International and Avista Capital Partners for US$1.53bn.

Belgium-headquartered UCB plans to use the proceeds to reduce its debt and increase its investments to accelerate growth and strengthen its medicines pipeline.

The deal is expected to close during the first quarter of 2015.

'This is another step for UCB to enhance focus on our core business in neurology and immunology,' said Roch Doliveux, CEO of UCB.

Detlef Thielgen, Chief Financial Officer of UCB, added that Kremers Urban had been 'an important enabler to build UCB's core business'.

'It's now the right time from a value perspective to focus on our core business and to offer Kremers Urban further growth opportunities with two strong organisations that are well equipped to help Kremers Urban continue to grow.'

  • Companies:
  • UCB
See more

You may also like

Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Read more
Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes
Packaging

Pharmapack Europe 2019 reveals winners

Award winners have been selected for innovation in delivery, dosage and packaging of pharmaceutical products
Pharmaceutical

Increasing competition in the psoriasis market

UCB, a global biopharmaceutical company, has potential to compete in the psoriasis market with Cimzia FDA approval, says GlobalData
Drug Delivery

UCB receives EMA approval for pre-filled pen using Bespak Technology

First disposable autoinjector for a biologic with Bespak technology to be approved by CHMP
Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Manufacturing

CPI-led UK biotech consortium secures £6.2m of government investment

Project aims to reduce the time it takes to bring biologics to market
Subscribe now